Ksaliproden

Из Википедије, слободне енциклопедије
Ksaliproden
Xaliproden.svg
IUPAC ime
1-[2-(2-naftil)etil]-4-[3-(trifluorometil)fenil]-1,2,3,6-tetrahidropiridin
Identifikatori
CAS broj 135354-02-8 ДаY
ATC kod N07XX03 (WHO)
PubChem CID 128919
ChemSpider 114237
UNII V8QL94KNQO ДаY
KEGG D06327 ДаY
Hemijski podaci
Formula C24H22F3N
Molarna masa 381,433 g/mol
  (verify)

Ksaliproden (SR57746) je lek koji deluje kao 5HT1A agonist.[1] On ima neurotrofno i neuroprotektivno dejstvo in vitro,[2][3] i predložen je kao potencijalni tretman za nekoliko neurodegenerativnih oboljenja, među kojima su amiotrofična lateralna skleroza (ALS)[4] i Alchajmerova bolest.[5]

Reference[уреди]

  1. Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). „MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden”. International journal of immunopathology and pharmacology. 18 (1): 21—31. PMID 15698508. 
  2. Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). „Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology. 127 (1): 139—44. doi:10.1038/sj.bjp.0702545. PMC 1566010слободно за читање. PMID 10369466. 
  3. Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). „Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology. 128 (7): 1385—92. doi:10.1038/sj.bjp.0702910. PMC 1571767слободно за читање. PMID 10602316. 
  4. Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). „Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 5 (2): 107—17. doi:10.1080/14660820410019602. PMID 15204012. 
  5. Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). „Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol. 37 (6): 321—7. doi:10.1097/00004424-200206000-00003. PMID 12021588. 

Spoljašnje veze[уреди]